© Reuters. FILE PHOTO: A logo of a testing company Qiagen is seen as Economy Minister Andreas Pinkwart and Health Minister Karl-Josef Laumann of the German state Northrhine Westphalia visit Qiagen’s facility, in Hilden, Germany, September 8, 2020. REUTERS/Leon Kuege
FRANKFURT (Reuters) – U.S.-German biotechnology company Qiagen (NYSE:) NV said on Thursday it was not currently affected by global supply chain bottlenecks as it had already been stockpiling supplies at its production facilities amid pandemic-related uncertainties.
The company, which makes genetic diagnostics kits including COVID-19 tests, can rely on its existing supplies for a few more weeks despite bottlenecks due to the recent pandemic outbreak in China, finance chief Roland Sackers told a news conference.
“Of course, in the medium term, we are also dependent on components that have to arrive. But the lockdown, especially in Shanghai, must be resolved soon,” Sackers said.
“Thank goodness we don’t have any products now that are highly perishable,” the CFO added.
Be the first to comment